Equity Profile

ROIV

Roivant Sciences Ltd.

Health CareBiotechnology$20.6B

May20Wed

Post-Earnings Recap

ReportedQ4-2025Pre-Market7:00 AM EDT

Roivant Sciences Beats on EPS, Stock Up 14.89%

Metric	Actual	Expected	Surprise
EPS	$0.28	$-0.35	+174.67%
Revenue	—	$4M	—

management commentary, guidance changes, and full analysis available with Pro.

Roivant Sciences Beats on EPS, Stock Up 14.89%

Key Numbers

Metric	Actual	Expected	Surprise
EPS	$0.28	$-0.35	+174.67%
Revenue	—	$4M	—

Management Commentary

Tone: Unknown

No transcript is on record, and the analysis is based solely on numerical results.

What It Means

Roivant Sciences reported a strong earnings surprise with an EPS of $0.28, significantly beating expectations. However, revenue figures were not disclosed, leaving some uncertainty. The stock reacted positively, rising nearly 15%, likely driven by the unexpected profitability in EPS.

Company Snapshot

Roivant Sciences Ltd. is a biotechnology company focused on advancing innovative therapies to improve patient outcomes....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

$-0.35

Revenue

Revenue figures provide insight into the company's sales performance and market demand for its products.

$4M

Wall Street expectations, options signals, track record, and call prep available with Pro.

Original Pre-Earnings Preview

Context

Company Snapshot

Roivant Sciences Ltd. is a biotechnology company focused on advancing innovative therapies to improve patient outcomes. Operating in the health care sector, Roivant is known for its unique approach to drug development and commercialization, which could play a significant role in addressing unmet medical needs.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

63%

Avg EPS Surprise

+61.93%

Avg Stock Reaction

+5.96%

Last Quarter Recap

In the last quarter, Roivant reported an EPS of $-0.38, slightly beating expectations of $-0.39. The stock reacted positively, rising by over 22% the following day.

Management Promises & Guidance

Continue to focus on advancing clinical trials for key therapies.
Maintain transparency in reporting progress and challenges.
Explore potential partnerships to enhance drug development.

Expectations

Wall Street Expectations

Analysts expect Roivant to report a loss this quarter, with a consensus EPS of $-0.35 and revenue of $4M. Investors will be keen to see if the company can meet or exceed these expectations.

Bull Case

If Roivant can report better-than-expected earnings and revenue, it may signal strong demand for its therapies and boost investor confidence.

Bear Case

Conversely, if the company misses its targets, it could raise concerns about its financial stability and future growth prospects.

Key Metrics to Watch

Earnings Per Share (EPS)

$-0.35

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

Revenue

$4M

Revenue figures provide insight into the company's sales performance and market demand for its products.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will Roivant's EPS meet or exceed the consensus estimate of $-0.35?

A beat on EPS could indicate improved operational efficiency and stronger market demand.

What revenue figures will Roivant report, and how do they compare to the $4M consensus?

Revenue performance is crucial for assessing the company's growth trajectory and market acceptance of its products.

Edge

What the Street Is Missing

Why consensus could be wrong

The consensus may underestimate Roivant's potential for revenue growth due to recent advancements in its clinical trials.

Supporting Evidence

The company has a history of surprising on EPS, with a 63% beat rate over the last eight quarters.

Recent insider selling could indicate confidence in the company's future performance despite current losses.

Key Risk

If revenue comes in significantly above $4M, it could challenge the current bearish outlook.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating Roivant's ability to generate revenue and control losses, which are critical for its future growth.

Bull Confirmed If

Reporting an EPS of $-0.26 or better, along with revenue exceeding $5M, would confirm the bull case.

Bear Confirmed If

An EPS worse than $-0.49 and revenue below $3M would support the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±7.00%

Historical Avg

±7.2%

In line with history

The options market is pricing in a significant move around the earnings report, suggesting that investors are anticipating volatility.

Options are pricing ±7.0% while ROIV has averaged ±7.2% over the last 8 prints — setup is roughly in line with history.

Detail

ATM IV

0.5%

30d HV

28.0%

Calls (39K)P/C Ratio: 0.16Puts (33K)

Edge

Insider Activity

Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.

Bought

$0.00

0 sh

0 insiders

Sold

$14.4M

489,774 sh

2 insiders

Net

$14.4M

Net selling

Most Active Insiders· 2 open-market trades

CEOGline Matthew
$8.4M
Net selling

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Roivant beats expectations, history suggests a potential stock increase of around 5.5%, confirming positive market sentiment.

In-Line / Cautious

If results are in line with expectations, the stock may experience a muted reaction, reflecting cautious investor sentiment.

Miss

A miss on earnings could lead to a decline, with historical data indicating an average drop of around 0.7%.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the progress of key clinical trials and their expected timelines.
2Any new partnerships or collaborations that could enhance revenue streams.
3Management's outlook on market conditions and competitive landscape.
4Details on cost management strategies to improve EPS.
5Insights into patient feedback and market reception for existing therapies.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Baidu, Inc.

Company Snapshot

Roivant Sciences Ltd. is a biotechnology company focused on advancing innovative therapies to improve patient outcomes....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

$-0.35

Revenue

Revenue figures provide insight into the company's sales performance and market demand for its products.

$4M

Wall Street expectations, options signals, track record, and call prep available with Pro.

Original Pre-Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

63%

Avg EPS Surprise

+61.93%

Avg Stock Reaction

+5.96%

Last Quarter Recap

In the last quarter, Roivant reported an EPS of $-0.38, slightly beating expectations of $-0.39. The stock reacted positively, rising by over 22% the following day.

Management Promises & Guidance

Continue to focus on advancing clinical trials for key therapies.
Maintain transparency in reporting progress and challenges.
Explore potential partnerships to enhance drug development.

Expectations

Wall Street Expectations

Analysts expect Roivant to report a loss this quarter, with a consensus EPS of $-0.35 and revenue of $4M. Investors will be keen to see if the company can meet or exceed these expectations.

Bull Case

If Roivant can report better-than-expected earnings and revenue, it may signal strong demand for its therapies and boost investor confidence.

Bear Case

Conversely, if the company misses its targets, it could raise concerns about its financial stability and future growth prospects.

Key Metrics to Watch

Earnings Per Share (EPS)

$-0.35

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

Revenue

$4M

Revenue figures provide insight into the company's sales performance and market demand for its products.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will Roivant's EPS meet or exceed the consensus estimate of $-0.35?

A beat on EPS could indicate improved operational efficiency and stronger market demand.

What revenue figures will Roivant report, and how do they compare to the $4M consensus?

Revenue performance is crucial for assessing the company's growth trajectory and market acceptance of its products.

Edge

What the Street Is Missing

Why consensus could be wrong

The consensus may underestimate Roivant's potential for revenue growth due to recent advancements in its clinical trials.

Supporting Evidence

The company has a history of surprising on EPS, with a 63% beat rate over the last eight quarters.

Recent insider selling could indicate confidence in the company's future performance despite current losses.

Key Risk

If revenue comes in significantly above $4M, it could challenge the current bearish outlook.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating Roivant's ability to generate revenue and control losses, which are critical for its future growth.

Bull Confirmed If

Reporting an EPS of $-0.26 or better, along with revenue exceeding $5M, would confirm the bull case.

Bear Confirmed If

An EPS worse than $-0.49 and revenue below $3M would support the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±7.00%

Historical Avg

±7.2%

In line with history

The options market is pricing in a significant move around the earnings report, suggesting that investors are anticipating volatility.

Options are pricing ±7.0% while ROIV has averaged ±7.2% over the last 8 prints — setup is roughly in line with history.

Detail

ATM IV

0.5%

30d HV

28.0%

Calls (39K)P/C Ratio: 0.16Puts (33K)

Edge

Insider Activity

Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.

Bought

$0.00

0 sh

0 insiders

Sold

$14.4M

489,774 sh

2 insiders

Net

$14.4M

Net selling

Most Active Insiders· 2 open-market trades

CEOGline Matthew
$8.4M
Net selling

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Roivant beats expectations, history suggests a potential stock increase of around 5.5%, confirming positive market sentiment.

In-Line / Cautious

If results are in line with expectations, the stock may experience a muted reaction, reflecting cautious investor sentiment.

Miss

A miss on earnings could lead to a decline, with historical data indicating an average drop of around 0.7%.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the progress of key clinical trials and their expected timelines.
2Any new partnerships or collaborations that could enhance revenue streams.
3Management's outlook on market conditions and competitive landscape.
4Details on cost management strategies to improve EPS.
5Insights into patient feedback and market reception for existing therapies.